Get the Stockscreener App
13.34
1.56%
-0.12
Cartesian Therapeutics Inc stock is traded at $13.34, with a volume of 12,055.
It is down -1.56% in the last 24 hours and up +23.14% over the past month.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
See More
Previous Close:
$13.46
Open:
$13.46
24h Volume:
12,055
Relative Volume:
0.17
Market Cap:
$343.38M
Revenue:
$26.00M
Net Income/Loss:
$-219.71M
P/E Ratio:
-0.2679
EPS:
-49.8
Net Cash Flow:
$-51.37M
1W Performance:
+11.91%
1M Performance:
+23.14%
6M Performance:
-30.99%
1Y Performance:
-20.08%
1-Day Range:
$12.56
$13.46
1-Week Range:
$11.80
$13.81
52-Week Range:
$8.46
$26.50
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Name
Cartesian Therapeutics Inc
Sector
Industry
Phone
301-348-8698
Address
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
13.23 | 347.53M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.57 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.70 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.74 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.96 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
292.44 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Aug-06-24 | Initiated | TD Cowen | Buy |
| Jul-02-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-04-24 | Initiated | Oppenheimer | Outperform |
| May-24-24 | Initiated | Mizuho | Buy |
| Apr-23-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-23-24 | Initiated | Leerink Partners | Outperform |
| Aug-18-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Jun-14-22 | Reiterated | Needham | Buy |
| Jun-06-22 | Initiated | SVB Leerink | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jan-26-21 | Upgrade | Mizuho | Neutral → Buy |
| Oct-01-20 | Downgrade | Mizuho | Buy → Neutral |
| Oct-01-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-12-20 | Downgrade | Stifel | Buy → Hold |
| Apr-28-20 | Initiated | H.C. Wainwright | Buy |
| Jan-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-20 | Initiated | William Blair | Outperform |
| Jun-27-18 | Initiated | Janney | Buy |
| Mar-30-17 | Reiterated | UBS | Buy |
View All
Cartesian Therapeutics Inc Stock (RNAC) Latest News
What drives Cartesian Therapeutics Inc. stock priceOutstanding trading profits - PrintWeekIndia
Is Cartesian Therapeutics Inc. stock a good hedge against inflationSuperior risk-adjusted returns - jammulinksnews.com
When is the best time to buy Cartesian Therapeutics Inc. stockBreakthrough capital growth - jammulinksnews.com
Is Cartesian Therapeutics Inc. a good long term investmentHigh-profit stock alerts - Autocar Professional
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate - Benzinga
Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last? - Yahoo Finance
Cartesian Therapeutics Inc. Stock Analysis and ForecastFree Daily Trading Room Entry - Autocar Professional
What analysts say about Cartesian Therapeutics Inc. stockFree Stock Market Forecast Reports - jammulinksnews.com
What makes Cartesian Therapeutics Inc. stock price move sharplyFree Stock Market Swing Trading Strategies - Newser
Multiple Myeloma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics - MenaFN
Why Cartesian Therapeutics Inc. stock attracts strong analyst attentionCarefully Curated High Return Stocks - Newser
How Cartesian Therapeutics Inc. stock performs during market volatilityShort Squeeze Radar - Newser
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $40.00 Average Price Target from Analysts - Defense World
What is Wedbush’s Estimate for RNAC Q2 Earnings? - Defense World
Cartesian Therapeutics Advances mRNA CAR T-cell Therapy for Myasthenia Gravis - TipRanks
Wedbush Initiates Coverage on Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
CartesianAutoimmune Cell Therapy Excites, But Reality Bites (NASDAQ:RNAC) - Seeking Alpha
Wedbush Initiates Cartesian Therapeutics(RNAC.US) With Buy Rating, Announces Target Price $38 - 富途牛牛
Wedbush initiates coverage on Cartesian Therapeutics stock with Outperform rating - Investing.com Canada
Cartesian stock up as Wedbush becomes bullish (RNAC:NASDAQ) - Seeking Alpha
Cartesian Therapeutics' 15min chart sees KDJ Golden Cross, bullish Marubozu formation. - AInvest
AbbVie Makes Big Autoimmune CAR-T Play With Capstan Acquisition - insights.citeline.com
What caused RNAC's earnings to miss forecasts in Q4 2023? - AInvest
Rhumbline Advisers Grows Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
We're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate - Yahoo Finance
Myasthenia Gravis Market to Expand Significantly by 2034, States DelveInsight Report | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - The Globe and Mail
IBM Introduces Industry-First Software to Unify Agentic Governance and Security - The Globe and Mail
Cartesian Therapeutics holds annual stockholders meeting By Investing.com - Investing.com South Africa
Cartesian Therapeutics holds annual stockholders meeting - Investing.com
Cartesian Therapeutics Holds Annual Stockholders Meeting - TipRanks
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Acquired by Bank of America Corp DE - Defense World
Cartesian Therapeutics Inc Stock (RNAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cartesian Therapeutics Inc Stock (RNAC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| English Emily | Chief Operations Officer |
Apr 15 '25 |
Option Exercise |
3.30 |
7,500 |
24,750 |
47,726 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
48,595 |
508,751 |
620,175 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
41,782 |
393,947 |
571,580 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
36,338 |
391,455 |
656,513 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
8,575 |
89,773 |
8,637,273 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
7,373 |
69,517 |
8,628,698 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
6,412 |
69,074 |
8,643,685 |
| SPRINGER TIMOTHY A | Director |
Mar 20 '25 |
Buy |
15.59 |
54,889 |
855,593 |
8,621,325 |
| SPRINGER TIMOTHY A | Director |
Mar 19 '25 |
Buy |
14.97 |
20,234 |
302,962 |
8,566,436 |
| SPRINGER TIMOTHY A | Director |
Mar 18 '25 |
Buy |
14.42 |
14,740 |
212,599 |
8,546,202 |
1.74%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):